BAN2401 Shows Promise in Treating Early Alzheimer Disease


A new drug called BAN2401 has shown promise in decreasing amyloid in early AD, according to results from a phase II study.

References1. Alzheimer’s Association International Conference. BAN2401 Phase 2 Data released at AAIC 2018. July 22-26, 2018, Chicago, ILL. Eisai Global. Eisai and biogen announce detailed results of phase II clinical study of BAN2401 in early Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2018. July 25, 2018.3. Swanson CJ, Zhang Y, Dhadda S, et al. Treatment of Early AD subjects with BAN2401, an Anti-Aβ Protofibril Monoclonal Antibody, Significantly Clears Amyloid Plaque and Reduces Clinical Decline. Abstract 27531.

Related Videos
Video 6 - "Utilization of Neuroimaging in Alzheimer’s Disease"
Video 5 - "Contribution of Multiple Pathways to the Development of Alzheimer’s Disease"
video 4 - "Amyloid Cascade Hypothesis of Alzheimer’s Disease"
Video 3 - "Amyloid Precursor Protein and Amyloid Beta Species in Alzheimer’s Disease"
Anton P. Porsteinsson, MD
© 2024 MJH Life Sciences

All rights reserved.